Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpelisib plus endocrine therapy in PIK3CA-mutant HR+/HER2- advanced breast cancer
NCT03056755Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2017
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 2 trial of alpelisib in breast cancer, sponsored by Novartis. Started Aug 2017; status: completed.
02
Drugs
alpelisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03056755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03056755.